News Eli Lilly and Company Borsa Italiana

Equities

4LLY

US5324571083

Real-time Estimate Tradegate Other stock markets 19:47:23 17/07/2024 BST			5-day change	1st Jan Change
835.8 ^EUR	-4.38%		+2.14%	+66.00%

06:24pm	Global markets live: Adidas, TSMC, Vale, HSBC, J&J...
04:18pm	Stocks to watch as Biden, Trump vie for presidency	RE

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Global markets live: Adidas, TSMC, Vale, HSBC, J&J...	05:24pm
Stocks to watch as Biden, Trump vie for presidency	03:18pm	RE
TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850	02:53pm	MT
Earnings reports take center stage as tech stocks tumble	02:38pm
Wall Street set to fall as megacap chip, tech stocks tumble	02:14pm	RE
ANALYST RECOMMENDATIONS : American Airlines, Chevron, UnitedHealth, Bank of America, Eli Lilly...	10:11am
Roche reports positive early results in obesity drug trial	07:13am	RE
Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly	07-16	MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793	07-16	MT
Novo owner backs Swiss biotech Asceneuron in $100 million round	07-16	RE
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	07-12	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	07-12	RE
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	07-12	MT
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating	07-12	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	07-12	RE
Neuroendocrine Tumors Pipeline 2024 \| Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene	07-12	AQ
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	07-11	DJ
Pfizer moves forward with once-daily weight loss drug	07-11	RE
JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating	07-11	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,083 From $1,023, Maintains Overweight Rating	07-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 06:47 pm